Banner - NPPA Connect

News


All News

Almirall announces the U.S. Food and Drug Administration has approved the updated label for their oral antibiotic sarecycline (Seysara) for treatment of acne vulgaris to help promote the appropriate use of the drug to aid in preventing antimicrobial resistance commonly warned when using antibiotics

ICYMI, this week’s edition features a video series on social media use in dermatology, the launch of our new podcast, as well as articles about FDA approvals for acne and cSCC, progress in epidermolysis bullosa, new rosacea management treatment, plus more.

Weekly Roundup

ICYMI, this week’s edition features articles about laser therapy for BCC, the growing interest in JAK-STAT inhibition, tips on how to sell your practice, apremilast for scalp pruritus, plus more.

The Mainstream Patient

In this week’s edition, we feature stories about black-owned skincare lines, polyglutamic acid, hair antioxidants, a skincare company making affordable custom topical prescriptions, plus many more.

Iltefat Hamzavi, MD

In part two of our interview with Iltefat H. Hamzavi, M.D., he delves into the data from a recent article investigating the use ultraviolet germicidal irradiation (UVGI) as a method to disinfect N95 respirators for reuse during the COVID-19 pandemic.

In this week’s edition, we highlight stories about ways to support people of color in the beauty industry aside from purchasing products, the safety of LED light therapy, dermaplaning at home, why your skin might be acting up right now, plus more.

In case you missed it, this week we featured stories involving blastic plasmacytoid dendritic cell neoplasm (BPDCN), development of a biosimilar to BOTOX, a new nonmelanoma treatment device, the latest phase 3 results for abrocitinib in atopic dermatitis, results from a long-term dabrafenib and trametinib study in stage 3 BRAF-mutated melanoma, plus many more.